Investing.com - ABVC Biopharma reported on Monday third quarter earnings that beat analysts' forecasts and revenue that topped expectations.
ABVC Biopharma announced earnings per share of $-0.11 on revenue of $42.27K. Analysts polled by Investing.com anticipated EPS of $-0.13 on revenue of $26.18K.
ABVC Biopharma shares are down 12% from the beginning of the year, still down 82.39% from its 52 week high of $4.26 set on December 10, 2021.
ABVC Biopharma follows other major Healthcare sector earnings this month
ABVC Biopharma's report follows an earnings beat by J&J on October 18, who reported EPS of $2.55 on revenue of $23.79B, compared to forecasts EPS of $2.48 on revenue of $23.36B.
Eli Lilly had beat expectations on November 1 with third quarter EPS of $1.98 on revenue of $6.94B, compared to forecast for EPS of $1.91 on revenue of $6.91B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar